Celldex Therapeutics (CLDX) Cash from Financing Activities (2010 - 2026)
Celldex Therapeutics (CLDX) posted quarterly Cash from Financing Activities of $327000.0 for Q1 2026, up 61.88% year-over-year from $202000.0 in Q1 2025, and down 75.76% quarter-over-quarter from $1.3 million in Q4 2025.
Celldex Therapeutics (CLDX) Cash from Financing Activities (2010 - 2026) Analysis & Trends
Celldex Therapeutics' Cash from Financing Activities history runs 17 years deep, the most recent figure standing at $327000.0 for Q1 2026.
- In Q1 2026, Cash from Financing Activities rose 61.88% year-over-year to $327000.0; the TTM figure through Mar 2026 stood at $2.5 million (down 54.63% YoY), while the FY2025 annual figure was $2.4 million, down 99.46% from the prior year.
- Cash from Financing Activities for Q1 2026 stood at $327000.0, down from $1.3 million in the prior quarter.
- The five-year high for Cash from Financing Activities was $436.1 million in Q1 2024, with the low at $63000.0 in Q2 2025.
- The 5-year median for Cash from Financing Activities is $694000.0 (2023), against an average of $39.2 million.
- The sharpest annual moves came in 2024 and 2025: Cash from Financing Activities jumped 62740.35% in 2024, then plunged 99.95% in 2025.
- Celldex Therapeutics' Cash from Financing Activities stood at $1.4 million in 2022, then jumped by 15482.37% to $217.4 million in 2023, then slumped by 99.82% to $386000.0 in 2024, then surged by 249.48% to $1.3 million in 2025, then slumped by 75.76% to $327000.0 in 2026.
- Business Quant data shows CLDX's Cash from Financing Activities at $327000.0 in Q1 2026, $1.3 million in Q4 2025, and $774000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -426.70 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -1.22 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.42 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | -6.05 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -207,909.22 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | -273.15 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 36.24 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 27.18 Mn |
| 10 | Celldex Therapeutics | 3.29 Bn | 2.58 Bn | -2.57 Mn | 324.66 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 324.66 Mn |
| Jun 30, 2026 | 324.66 Mn |
| Mar 31, 2026 | 327,000.00 |
| Mar 31, 2026 | 327,000.00 |
| Dec 31, 2025 | 1.35 Mn |
| Dec 31, 2025 | 1.35 Mn |
| Sep 30, 2025 | 774,000.00 |
| Sep 30, 2025 | 774,000.00 |
| Jun 30, 2025 | 63,000.00 |
| Jun 30, 2025 | 63,000.00 |
| Mar 31, 2025 | 202,000.00 |
| Mar 31, 2025 | 202,000.00 |
| Dec 31, 2024 | 386,000.00 |
| Dec 31, 2024 | 386,000.00 |
| Sep 30, 2024 | 1.24 Mn |
| Sep 30, 2024 | 1.24 Mn |
| Jun 30, 2024 | 3.71 Mn |
| Jun 30, 2024 | 3.71 Mn |
| Mar 31, 2024 | 436.11 Mn |
| Mar 31, 2024 | 436.11 Mn |